Dry Eye News and Research

RSS

Dry eye is one of the most common complaints seen by eye doctors, accounting for nearly one fourth of all office visits. Caused by insufficient tear production or excessive tear evaporation, dry eye can be a mild, episodic feeling of discomfort associated with certain circumstances, such as exposure to dry, hot or windy environments; however, it can also be a chronic medical condition that, if left untreated, may lead to increased risk of infection or visual impairment.

Eleven Biotherapeutics announces first pivotal Phase 3 clinical study of EBI-005 for treatment of DED

Eleven Biotherapeutics (NASDAQ: EBIO), a clinical-stage biopharmaceutical company discovering and developing protein therapeutics to treat diseases of the eye, today announced that patient randomization and dosing are underway in the Company's first pivotal Phase 3 clinical study of EBI-005 for the treatment of moderate to severe dry eye disease (DED), the OASIS study (A Multi-Center, Double-Masked, Randomized, Controlled, Efficacy and Safety Study of EBI-005 5 mg/mL Topical Ophthalmic Solution Versus Vehicle Control In Subjects With Moderate to Severe Dry Eye Disease).

19 Feb 2014

ARIAD Pharmaceuticals' Iclusig now commercially available to patients in the U.S.

ARIAD Pharmaceuticals, Inc. today announced the commercial availability of Iclusig (ponatinib) for adult patients with refractory chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia in the United States. ARIAD has begun shipping Iclusig to Biologics, Inc., its exclusive specialty pharmacy, which is now filling prescriptions from physicians and distributing the cancer medicine to patients.

18 Jan 2014

CF101 drug fails to meet primary efficacy endpoint in phase III study for Dry Eye Syndrome

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that its subsidiary OphthaliX Inc. released results from a 24 week, placebo-controlled phase III study involving 237 patients with moderate-to-severe Dry Eye Syndrome who were treated with its licensed drug CF101, an A3 adenosine receptor agonist.

30 Dec 2013

Researchers identify potential therapy for meibomian gland dysfunction

Meibomian gland dysfunction is the leading cause of dry eye disease, which affects tens of millions of Americans. However, there is no FDA-approved treatment for MGD. Researchers from the Schepens Eye Research Institute/Massachusetts Eye and Ear and Harvard Medical School have just identified a potential therapy.

24 Dec 2013

Residents of major cities with high pollution levels have increased risk of dry eye syndrome

Residents of major cities with high levels of air pollution have an increased risk of dry eye syndrome, according to a study presented at the world's largest ophthalmic conference, the 117th Annual Meeting of the American Academy of Ophthalmology, in New Orleans.

17 Nov 2013

Neuroptis Biotech reports positive results from ML7 preclinical trials for eye surface diseases

Neuroptis Biotech, the ophthalmology drug research and development specialist, announces positive results in preclinical trials of the eye-drop formulation of its ML7 product. ML7 is intended for use in the treatment of eye surface diseases, particularly dry eye.

13 Nov 2013

Dry eye disease symptom change independent of tear osmolarity

Tear osmolarity is a poor indicator of treatment response in patients with dry eye disease (DED), suggests research published in the American Journal of Ophthalmology.

9 Oct 2013

Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200

Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.

9 Oct 2013

Altaire Pharmaceuticals recalls 9 lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution

Altaire Pharmaceuticals, Inc., announces today that it is voluntarily recalling a total of nine (9) lots of Carboxymethylcellulose Sodium 0.5% Ophthalmic Solution, 30 mL, to the consumer level. There have been no reports of adverse effects to consumers so far.

7 Sep 2013

Rigel Cuts 30 Jobs, Refocuses On Three Clinical Programs

...

5 Sep 2013

Rigel plans to focus on completing three clinical programs for ITP, DLE and dry eye disease

Rigel Pharmaceuticals, Inc. today announced its plans to focus the Company's resources on the completion of three lead clinical programs. These efforts include commencing a Phase 3 clinical study of fostamatinib, an oral SYK inhibitor, in Immune Thrombocytopenic Purpura pending discussions with regulatory agencies.

5 Sep 2013

Study: Daily dietary supplementation with blend of omega fatty acids improves severe dry eye

Study findings published online, ahead of print, in Cornea show that daily dietary supplementation with a unique combination of omega fatty acids (GLA, EPA and DHA) for six months is effective in improving ocular irritation symptoms and halting the progression of inflammation that characterizes moderate to severe dry eye.

25 Jul 2013

Novaliq receives CE mark approval for EyeSol technology

Novaliq GmbH, a drug delivery company with a focus on the topical application of ophthalmic technologies for poorly soluble drugs, today announced the successful CE mark approval for the first topical eye lubricant based on Novaliq's proprietary technology EyeSol.

23 Jul 2013

Bausch + Lomb obtains option to license MIM-D3 for treatment of dry eye syndrome

Bausch + Lomb, the global eye health company, and Mimetogen Pharmaceuticals Inc. today announced that Bausch + Lomb has acquired an option to license an investigational compound currently in Phase 2 development for the treatment of dry eye syndrome, a condition that affects millions of people worldwide.

19 Jul 2013

Eleven Biotherapeutics reports positive results from EBI-005 Phase 1b/2a study in patients with DED

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today positive topline clinical results from a 6-week randomized, double-masked, placebo-controlled Phase 1b/2a study of EBI-005 in patients with dry eye disease.

28 Jun 2013

Recombinant human albumin from Novozymes Biopharma helps innovative dry eye therapy move into clinical trials

Novozymes Biopharma, part of Novozymes A/S world leader in bioinnovation, today announced that an ophthalmic solution made using its recombinant human albumin, has been approved for Phase I/II development by the FDA.

20 May 2013

Phase 1b clinical study data of EBI-005 for treatment of dry eye disease presented at ARVO meeting

Eleven Biotherapeutics, a biopharmaceutical company designing and engineering novel and differentiated protein-based biotherapeutics for ocular diseases, announced today the presentation of data for EBI-005, the first IL-1 (Interleukin-1) signaling inhibitor designed for topical ocular administration, at the Association for Research in Vision and Ophthalmology 2013 Annual Meeting in Seattle, Washington.

9 May 2013

Rigel reports net loss of $25.6 million in first quarter 2013

Rigel Pharmaceuticals, Inc. today reported financial results for the first quarter ended March 31, 2013. For the first quarter of 2013, Rigel reported a net loss of $25.6 million, or $0.29 per share, compared to a net loss of $23.2 million, or $0.32 per share, in the first quarter of 2012. Weighted average shares outstanding for the first quarters of 2013 and 2012 were 87.1 million and 71.4 million, respectively.

7 May 2013

IL-1 antagonist relieves dry eyes

Clinical trial results point to a role for interleukin-1 targeted agents for the treatment of dry eye disease associated with meibomian gland dysfunction.

29 Apr 2013

Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA associated with dry AMD

Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 clinical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dry age-related macular degeneration has been initiated.

25 Apr 2013